JİNEKOLOJİK TÜMÖRLERDE ÜÇ
BOYUTLU KONFORMAL RADYOTERAPİ
JİNEKOLOJİK TÜMÖRLERDE
RADYOTERAPİ
Radyoterapi, jinekolojik tümörlerin gerek primer gerekse postoperatif adjuvant tedavi olarak küratif tedavinin önemli bir parçasıdır. Bu gaye ile uygulanacak radyoterapi volümü primer tümör veya tümör yatağı ile ilgili bölgesel lenf nodlarını kapsamalıdır. Tedavi başarısı açısından sağkalım ve toksisite kadar yaşam kalitesi de önemli bir kriterdir. Teknolojik gelişmelerin radyoterapi üzerine yansıması ve 3 boyutlu tedavilere geçiş ile arzulanan sonuçlara ulaşma oranları artmıştır. Yapılan birçok çalışma ile konvansiyonel yöntemlerde kemik referansların kullanılması ile gerekli tedavi alanlarının kapsanmadığı gösterilmiştir. Hedef hacmin daha iyi saptanması, daha uygun doz dağılımı, daha az erken ve geç yan etki, tümörde daha yüksek doza ulaşma, daha iyi lokal kontrol, daha iyi yaşam kalitesi ve sağkalım gereksinimleri 3 boyutlu konformal radyoterapinin güncel tedavi stratejisi olmasını zorunlu kılmıştır. İyi tasarlanmış bir simülasyon işlemi sonrasında hedef hacimler ve risk altındaki organlar titizlikle belirlenmelidir. Planlamada kullanılan hedef hacimler Uluslararası Radyasyon Birim ve Ölçümleri Komisyonu (International Commission on Radiation Units and Measurement-ICRU)’nun 50 ve 62 numaralı raporlarına göre düzenlenmektedir. Anatomik yapıları daha net ayırarak planlamaya yardımcı olması amacı ile tedavi pozisyonunda alınan dozimetrik magnetik rezonans (MR) görüntüleri rutin olarak kullanılmalıdır. Ayrıca gelecekte BT-MR görüntü birleştirme işleminin daha yaygın kullanılabilme imkânı olabileceği ümit edilmektedir. Sonrasında planlama sistemleri üzerinden tedavi alanlarının ve dozlarının belirlenmesi ile güvenilir bir biçimde radyoterapi uygulanabilmektedir. Sonuç olarak tüm gelişmiş ülkelerde ve ülkemizdeki büyük merkezde 3 boyutlu konformal tedavi standart olarak kullanılmaktadır. Ekip çalışması ile tüm aşamalar titizlikle yapılmalıdır ve her aşamanın denetimi ile tedavi kalitesinin arttırılacağı unutulmamalıdır
THREE DIMENSIONAL CONFORMAL
RADIOTHERAPY AT GYNECOLOGICAL
MALIGNANCIES
Radiotherapy is an important part of both primary and postoperative adjuvant treatments of gynecological tumors. With this goal radiotherapy volume should include the primary tumor or tumor bed and regional lymph nodes. Quality of life is also important criteria such as survival and toxicity for treatment success. The rate of desired results have increased with reflection of tecnological developments on radiotherapy and the passage of 3-dimensional treatments. Many studies have shown that the use of bone references in conventional methods are not covered the necessary treatment areas. Three-dimensional conformal radiotherapy became the current treatment strategy for a better determination of the target volume, more convenient dose distribution, less early and late side-effects, higher tumor dose ,better local control ,better quality of life and survival. After a well-designed simulation, target volumes and organs at risk should be determined carefully. International Commission on Radiation Units and Measurements’s 50 and 62 reports are used for arranged planning target volumes. The dosimetric magnetic resonance images in treatment position are routinely used to help planning by seperation the anatomical structures more clearly. After that, the radiotherapy can be applied in a reliable manner by the determination of treatment areas and doses at planning systems. As a result, three-dimensional conformal radiotherapy is used as standard treatment in all developed countries and the great centers of our country. All steps should be done carefully with teamwork and it should be noted that the quality of treatment will be increased with the control of each stages
___
- 1. Withers HR, Peters LJ, Taylor JMG. Dose-response relationship
for radiation therapy for subclinical disease. Int J
Radiat Oncol Biol Phys 1995;31:353-359.
- 2. Zunino S, Rosato O, Lucino S, Jauregui E, Rossi L, Venencia
D. Anatomic study of the pelvis in the carcinoma of
the uterine cervix as related to the box technique.. Int J
Radiat Oncol Biol Phys 1999;44:53-59.
- 3. Kim RY, McGinnis S, Spencer SA, Meredith RF, Jennelle
RL, Salter MM. Conventional four-fi eld pelvic radiotherapy
technique without computer tomography-treatment
planning in cancer of the cervix: Potential geographic
miss and its impact on pelvic control.. Int J Radiat Oncol
Biol Phys 1995;31:109-112.
- 4. Greer BE, Koch WJ, Figge DC, Shy KK, Tamimi HK.
Gynecologic radiotherapy fi elds defi ned by intraoperative
measurements. Gynecol Oncol 1990;38:421-424.
- 5. McAlpine J, Schlaerth JB, Lim P, Chen D, Eisenkop SM,
Spirtos MM. Radiation fi elds in gynecologic oncology:
Correlation of soft tissue (surgical) to radiologic landmarks.
Gynecol Oncol 2004;92:25-30.
- 6. Pendlebury SC, Cahill S, Crandon AJ, Bull CA. Role of
bipedal lymphangiogram in radiation treatment planning
for cervix cancer.. Int J Radiat Oncol Biol Phys
1993;27:959-962.
- 7. Bonin SR, Lanciano RM, Corn BW, Hogan WM, Hartz
WH, Hanks GE. Bony landmarks are not adequate substitute
for lymphangiography in defi ning pelvic lymph node
location for the treatment of cervical cancer with radiotherapy..
Int J Radiat Oncol Biol Phys 1996;34:167-172
- 8. Chao KS, Lin M. Lymphangiogram-assisted lymph node
target delineation for patients with gynecologic malignancies..
Int J Radiat Oncol Biol Phys 2002;54:1147-1152.
- 9. Finlay MH, Ackerman I, Tirona RG, Hamilton P, Barbera
L, Thomas G. Use of CT simulation for treatment of cervical
cancer to assess the adequacy of lymph node coverage
of conventional pelvic fi elds based on bony landmarks..
Int J Radiat Oncol Biol Phys 2006;54:205-209.
- 10. ICRU Report 50: Prescribing, recording and reporting
photon beam therapy, Bethesda, MD: International Commission
on Radiation Units and Measurements, 1993.
- 11. ICRU Report 62: Prescribing, recording and reporting
photon beam therapy, (Supplement to ICRU Report 50).
Bethesda, MD: International Commission on Radiation
Units and Measurements, 1999.
- 12. Gregoire V, Haustermans K, Geets X, Roels S, Lonneux
M. PET-based treatment planning in radiotherapy: a new
standard? J Nucl Med 2007;48:68S-77S.
- 13. Thomas L, Chacon B, Kind M, Lasbareilles O, Muyldermans
P, Chemin A, Le Treut A, Pigneux J, Kantor G.
Magnetic resonance imaging in the treatment planning of
radiation therapy in carcinoma of the cervix treated with
the four-fi eld pelvic technique. Int J Radiat Oncol Biol
Phys 1997;37:827-832.
- 14. Barillot I, Reynaud-Bougnoux A. The use of MRI in planning
radiotherapy for gynecological tumors. Cancer Imaging
2006;6:100-106.
- 15. Lai CH, Yen TC, Chang TC. Positron emission tomography
imaging for gynecologic malignancy. Curr Opin
Obstetr Gynecol 2007;19:37-41.
- 16. Yen TC, Lai CH. Positron emission tomography in gynecologic
cancer. Semin Nucl Med 2006;36:93-104.
- 17. Taylor A, Rockall AG, Reznek RH, Powell ME. Mapping
pelvic lymph nodes: Guidelines for delineation in intensity-modulated
radiotherapy. Int J Radiat Oncol Biol Phys
2005;63:1604-1612.
- 18. Small W, Mell LK, Anderson P, Creutzberg C, De Los Santos
J, Gaffney D, Jhingran A, Portelance L, Schefter T, Iyer
R, Varia M, Winter K, Mundt AJ. Consensus guidelines
for delineation of clinical target volume for intensity-modulated
pelvic radiotherapy in postoperative treatment of
endometrial and cervical cancer.. Int J Radiat Oncol Biol
Phys 2008;71:428-434.
- 19. Lim K, Small W, Portelance L, Creutzberg C, JürgenliemkSchulz
I, Mundt A, Mell LK, Mayr N, Viswanathan A,
Jhingran A, Erickson B, De Los Santos J, Gaffney D, Yashar
C, Beriwal S, Wolfson A, Taylor A, Bosch W, Naqa I, Fyles
A. Consensus guidelines for delineation of clinical target
volume for intensity-modulated pelvic radiotherapy
for the defi nitive treatment of cervix cancer. Int J Radiat
Oncol Biol Phys 2010, article in press. Doi:10.1016/j.ijrobp.2009.10.075
- 20. Höckel M, Horn LC, Fritsch H. Association between
the mesenchymal compartment of uterovaginal organogenesis
and local tumor control spread in stage IB-IIB
cervical carcinoma: A prospective study. Lancet Oncol
2005;6:751-756.
- 21. Diaz JP, Sonoda Y, Leitao MM, Zivanovic O, Brown CL,
Chi DS, Barakat RR, Abu-Rustum NR. Oncologic outcome
of fertility-sparing radical trachelectomy versus radical
hysterectomy for stage IB1 cervical carcinoma. Gynecol
Oncol 2008;111:255-260.
- 22. Hertel H, Köhler C, Grund D, Hillemans P, Possover M,
Michels W, Scheider A. Radical vaginal trachelectomy
(RTV) combined with laparoscopic pelvic lymphadenectomy:
Prospective multicenter study of 100 patients with
early cervical cancer. Gynecol Oncol 2006;103:506-511.
- 23. Buchali A, Koswig S, Dinges S, Rosenthal P, Salk J, Lackner
G, Böhmer D, Schlenger L, Budach V. Impact of the
fi lling status of the bladder and rectum on their integral
dose distribution and the movement of the uterus in the
treatment planning of gynecological cancer. Radiother
Oncol 1999;52:29-34.
- 24. Emami B, Lyman J, Brown A, Coia L, Goiten M, Munzenrider
JE, Shank B, Solin LJ, Wesson M. Tolerance of normal
tissue to therapeutic irradiation. Int J Radiat Oncol
Biol Phys 1991;21:109-122.
- 25. Bentzen SM, Constine LS, Deasy JO, Eisbruch A, Jackson
A, Marks LB, Ten Haken RK, Yorke ED. Quantitative
analyses of normal tissue effects in the clinic (QUANTEC):
An introduction to the scientifi c issues. Int J Radiat
Oncol Biol Phys 2010:3:S3-S9.
- 26. Kavanaghi BD, Pan CC, Dawson LA, Das SK, Li XA, Ten
Haken RK, Miften M. Radiation dose-volume effects in
the stomach and small bowel. Int J Radiat Oncol Biol
Phys 2010:3:S101-S107.